Britain will have to strike new international agreements with other countries to maintain access to nuclear power technology after indicating that it is minded to leave Euratom, which has controlled the peaceful use of nuclear energy on the continent since 1957. The UK’s ability to ensure a reliable and consistent supply of pharmaceuticals is highly vulnerable to supply chain disruption. Lack of in-country manufacturing capability makes us reliant on overseas imports, which in turn are vulnerable to market pressures and international trade arrangements.
RUSI 21st July 2017 read more »